PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26344721-0	2015	Calnexin is a novel sero-diagnostic marker for lung cancer.	sero	20-24	calnexin	Homo sapiens	0-8
26344721-8	2015	To our knowledge, the present results provide evidence that CANX may be a novel sero-diagnostic marker for lung cancer.	sero	80-84	calnexin	Homo sapiens	60-64
26350112-7	2015	TPTE sero-positivity was not associated with tumor stage, tumor histology, gender or age.	sero	5-9	transmembrane phosphatase with tensin homology	Homo sapiens	0-4
26350112-8	2015	Multivariate analysis indicated that TPTE sero-positivity is associated with prolonged survival in patients with lung cancer, but established prognostic factors for survival prediction such as stage and histology remain indispensable.	sero	42-46	transmembrane phosphatase with tensin homology	Homo sapiens	37-41
26350112-10	2015	TPTE sero-reactivity has moderate sensitivity and specificity for diagnosing lung cancer and is a positive prognostic marker.	sero	5-9	transmembrane phosphatase with tensin homology	Homo sapiens	0-4
25204999-9	2014	Five patients sero-converted during the course of the study for anti-PF4/heparin IgG: 3 (4.1%) at week 1, 4 (5.5%) at week 2, and 5 (6.8%) at week 3 after surgery.	sero	14-18	platelet factor 4	Homo sapiens	69-72
26160751-0	2015	Structural and biophysical analysis of sero-specific immune responses using epitope grafted Dengue ED3 mutants.	sero	39-43	ectodysplasin-A receptor	Mus musculus	99-102
26160751-6	2015	E2 played a major role in the sero-specificity of anti-DEN3 serum, whereas E1 was important for DEN4 ED3"s sero-specificity.	sero	107-111	ectodysplasin-A receptor	Mus musculus	101-104
25233937-2	2014	In Sri Lanka, the first sero-positive case was reported in the 1960s; since then the island has experienced several outbreaks of DF/dengue haemorrhagic fever (DHF).	sero	24-28	sorcin	Homo sapiens	3-6
24189572-5	2014	Using the numbers of JCV sero-positive and -negative patients from a study of PML risk by JCV serologic status (sero-positive: 13,950 and sero-negative: 11,414), we apply a range of sensitivities and specificities in order calculate the number of JCV-exposed but JCV sero-negative patients (false negatives).	sero	94-98	PML nuclear body scaffold	Homo sapiens	78-81
25184165-6	2014	The results showed significant risk factors for AI (H5) sero-positivity in ducks were wooden egg box containers (OR = 52.7, 95% CI = 2.34-1188, P = 0.013) and water sourced from wetlands (OR = 30.7, 95% CI = 1.96-481.6, P = 0.015).	sero	56-60	H1 histone family, member 0	Gallus gallus	48-54
24609497-5	2014	In addition, recombinant MDH showed sero-reactivity with 30 individual bovine B. abortus-positive sera by enzyme-linked immunosorbent assay, indicates that MDH may be used as a candidate marker for sero-diagnosis of brucellosis.	sero	36-40	malate dehydrogenase 2	Homo sapiens	25-28
24189572-6	2014	We then apply a range of rates of developing PML in sero-negative patients to calculate the expected number of PML cases.	sero	52-56	PML nuclear body scaffold	Homo sapiens	45-48
24189572-8	2014	With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate.	sero	72-76	PML nuclear body scaffold	Homo sapiens	109-112
24189572-8	2014	With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate.	sero	72-76	PML nuclear body scaffold	Homo sapiens	171-174
24189572-8	2014	With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate.	sero	187-191	PML nuclear body scaffold	Homo sapiens	109-112
24189572-8	2014	With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate.	sero	187-191	PML nuclear body scaffold	Homo sapiens	171-174
24763718-7	2014	In contrast, the DQB1*06:03 haplotype was positively associated with JCV sero-status, in Scandinavian MS cases (OR = 1.63, p = 0.006), and controls (OR = 2.69, p = 1x10(-5)).	sero	73-77	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	17-21
22439015-0	2012	CAXII Is a sero-diagnostic marker for lung cancer.	sero	11-15	carbonic anhydrase 12	Homo sapiens	0-5
23083038-5	2012	RESULTS: The plasma BlyS level in sero-negative RA was higher compared to the sero-positive RA patients (1.73+-1.71 vs. 0.99+-0.59 ng/mL, P<0.05) and osteoarthritis (OA) patients (1.73+-1.71 vs. 0.59+-0.12 ng/mL, P<0.05).	sero	34-38	TNF superfamily member 13b	Homo sapiens	20-24
22426972-0	2012	Anti-HuC and -HuD autoantibodies are differential sero-diagnostic markers             for small cell carcinoma from large cell neuroendocrine carcinoma of the lung.	sero	50-54	ELAV like RNA binding protein 3	Homo sapiens	5-8
22430193-8	2012	Of the 1338 HCC patients, 616 (46%) and 686 (51.3%) were sero-positive for AFP and HCCR-1, respectively.	sero	57-61	alpha fetoprotein	Homo sapiens	75-78
22430193-8	2012	Of the 1338 HCC patients, 616 (46%) and 686 (51.3%) were sero-positive for AFP and HCCR-1, respectively.	sero	57-61	LETM1 domain containing 1	Homo sapiens	83-89
22971020-0	2013	Mucosal serpin A1 and A3 levels in HIV highly exposed sero-negative women are affected by the menstrual cycle and hormonal contraceptives but are independent of epidemiological confounders.	sero	54-58	serpin family A member 1	Homo sapiens	8-17
22515293-5	2012	FoxP3fl and Delta2 mRNA in SF CD4+ T cells was increased compared to controls in sero-negative RA and PsA, but not in sero-positive RA patients, who had a high FoxP3 expression in both PB and SF.	sero	81-85	forkhead box P3	Homo sapiens	0-5
22343159-9	2012	CONCLUSIONS: Repeating the test using a different assay or CSF is helpful to clarify whether sero-negative NMO patients do in fact carry AQP4 antibodies.	sero	93-97	aquaporin 4	Homo sapiens	137-141
22837089-10	2012	1 (2.5%) of the control was sero-positive for crag.	sero	28-32	ArfGAP with GTPase domain, ankyrin repeat and PH domain 3	Homo sapiens	46-50
22439015-10	2012	To further confirm the utility of serum CAXII levels as a sero-diagnostic marker, an additional set consisting of sera from 26 lung cancer patients and 30 healthy controls was also investigated by dot blot analysis as a validation study.	sero	58-62	carbonic anhydrase 12	Homo sapiens	40-45
22439015-13	2012	To our knowledge, this is the first report providing evidence that CAXII may be a novel sero-diagnostic marker for lung cancer.	sero	88-92	carbonic anhydrase 12	Homo sapiens	67-72
19099446-7	2009	Comparison of the OH stretch RIDIR spectrum of the third SERO-(H(2)O)(1) conformer with calculation leads to its assignment to a structure in which the water molecule forms a H-bonded bridge between the amino group and the 5-OH group of SERO, with the ethylamine side chain in the Gph(out) conformation that facilitates bridge formation, corresponding to the second most populated conformer in the isolated SERO monomer.	sero	57-61	gephyrin	Homo sapiens	281-284
20859505-4	2010	Hence a study was designed to find the sero-status of B19 virus in normal voluntary blood donor population (relatives of recipients) as an indirect measure of the susceptibility to B19 in north Indians together with seroepidemiology of B19.	sero	39-43	eva-1 homolog C	Homo sapiens	54-57
20859505-4	2010	Hence a study was designed to find the sero-status of B19 virus in normal voluntary blood donor population (relatives of recipients) as an indirect measure of the susceptibility to B19 in north Indians together with seroepidemiology of B19.	sero	39-43	eva-1 homolog C	Homo sapiens	181-184
20064498-6	2010	In 70 HCC patients who underwent curative hepatectomy, 39 patients sero-positive for the methylated CCND2 gene (>70pg/ml serum) exhibited a significantly shorter disease-free survival (DFS) period (P=0.02) than the 31 patients who were sero-negative for the methylated CCND2 gene.	sero	67-71	cyclin D2	Homo sapiens	100-105
20064498-6	2010	In 70 HCC patients who underwent curative hepatectomy, 39 patients sero-positive for the methylated CCND2 gene (>70pg/ml serum) exhibited a significantly shorter disease-free survival (DFS) period (P=0.02) than the 31 patients who were sero-negative for the methylated CCND2 gene.	sero	67-71	cyclin D2	Homo sapiens	272-277
20064498-6	2010	In 70 HCC patients who underwent curative hepatectomy, 39 patients sero-positive for the methylated CCND2 gene (>70pg/ml serum) exhibited a significantly shorter disease-free survival (DFS) period (P=0.02) than the 31 patients who were sero-negative for the methylated CCND2 gene.	sero	239-243	cyclin D2	Homo sapiens	100-105
20498762-9	2010	CONCLUSIONS: It was concluded that expression of IL-10 by gingival mononuclear cells and patients" sero-reactivity to the cross-reactive HSP peptide of P. gingivalis HSP60 were significantly correlated with alveolar bone height.	sero	99-103	interleukin 10	Homo sapiens	49-54
20498762-9	2010	CONCLUSIONS: It was concluded that expression of IL-10 by gingival mononuclear cells and patients" sero-reactivity to the cross-reactive HSP peptide of P. gingivalis HSP60 were significantly correlated with alveolar bone height.	sero	99-103	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	137-140
19099446-7	2009	Comparison of the OH stretch RIDIR spectrum of the third SERO-(H(2)O)(1) conformer with calculation leads to its assignment to a structure in which the water molecule forms a H-bonded bridge between the amino group and the 5-OH group of SERO, with the ethylamine side chain in the Gph(out) conformation that facilitates bridge formation, corresponding to the second most populated conformer in the isolated SERO monomer.	sero	237-241	gephyrin	Homo sapiens	281-284
19099446-7	2009	Comparison of the OH stretch RIDIR spectrum of the third SERO-(H(2)O)(1) conformer with calculation leads to its assignment to a structure in which the water molecule forms a H-bonded bridge between the amino group and the 5-OH group of SERO, with the ethylamine side chain in the Gph(out) conformation that facilitates bridge formation, corresponding to the second most populated conformer in the isolated SERO monomer.	sero	237-241	gephyrin	Homo sapiens	281-284
19099446-8	2009	The OH and CH stretch infrared absorptions for the single observed conformer of SERO-(H(2)O)(2) indicate that it is also a bridge structure linking the NH(2) and OH groups of SERO, retaining the same Gph(out) ethylamine conformation as in conformer C of SERO-(H(2)O)(1).	sero	80-84	gephyrin	Homo sapiens	200-203
18313840-4	2008	The DNA concentrations were significantly higher in HCC patients compared to HBV and HCV carriers without cancer, and to sero-negative individuals.	sero	121-125	HCC	Homo sapiens	52-55
17278093-8	2007	A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients.	sero	120-124	cancer/testis antigen 1A	Homo sapiens	189-197
12584747-8	2003	Using a secondary SEREX approach we could detect sero-reactivity in sera of CTCL patients against recombinant cTAGE-1 (10/29), GAGE (3/19), MAGE-A1 (1/18), -A3 (1/18), -A6 (2/18) and -A9 (4/18) protein, but not against LAGE-1a, MAGE-A4b or MAGE-A12 protein (n = 19).	sero	49-53	cutaneous T cell lymphoma-associated antigen 1	Homo sapiens	110-117
17441676-5	2007	An increase in the CD4 T cell response was observed in 2 of 2 initially sero-positive and 5 of 7 initially sero-negative patients after vaccination.	sero	72-76	CD4 molecule	Homo sapiens	19-22
17441676-5	2007	An increase in the CD4 T cell response was observed in 2 of 2 initially sero-positive and 5 of 7 initially sero-negative patients after vaccination.	sero	107-111	CD4 molecule	Homo sapiens	19-22
17441676-6	2007	An increase in the CD8 T cell response was also observed in 2 of 2 sero-positive and 5 of 7 sero-negative patients after vaccination.	sero	67-71	CD8a molecule	Homo sapiens	19-22
17441676-6	2007	An increase in the CD8 T cell response was also observed in 2 of 2 sero-positive and 5 of 7 sero-negative patients after vaccination.	sero	92-96	CD8a molecule	Homo sapiens	19-22
12839582-6	2003	Sero-reactivity against cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B was found only in tumor patients (cutaneous T cell lymphoma and melanoma).	sero	0-4	cutaneous T cell lymphoma-associated antigen 1	Homo sapiens	24-31
12839582-6	2003	Sero-reactivity against cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B was found only in tumor patients (cutaneous T cell lymphoma and melanoma).	sero	0-4	CTAGE family member 4	Homo sapiens	33-40
12839582-6	2003	Sero-reactivity against cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B was found only in tumor patients (cutaneous T cell lymphoma and melanoma).	sero	0-4	cutaneous T cell lymphoma-associated antigen 1	Homo sapiens	24-29
12839582-6	2003	Sero-reactivity against cTAGE-1, cTAGE-4, cTAGE-5A, and cTAGE-5B was found only in tumor patients (cutaneous T cell lymphoma and melanoma).	sero	0-4	cutaneous T cell lymphoma-associated antigen 1	Homo sapiens	33-38
17355134-7	2007	The conformational preferences of serotonin differ from those of tryptamine most notably in the selective stabilization observed for the Gph(out)/anti-OH conformer SERO(C), which makes it the second-most intense transition in the ultraviolet spectrum, surpassed only by the Gpy(out)/anti-OH conformer SERO(A).	sero	164-168	gephyrin	Homo sapiens	137-140
17355134-7	2007	The conformational preferences of serotonin differ from those of tryptamine most notably in the selective stabilization observed for the Gph(out)/anti-OH conformer SERO(C), which makes it the second-most intense transition in the ultraviolet spectrum, surpassed only by the Gpy(out)/anti-OH conformer SERO(A).	sero	301-305	gephyrin	Homo sapiens	137-140
17196133-7	2006	When the duration of treatment reached 1 year and 1.5 years, HBV DNA rebound rate in the patients (40.0% and 40.0% respectively) with HBeAg sero-conversion was obviously less (chi2 = 12.424, 10.237, P<0.01) than in those without sero-conversion (88.2% and 85.0% respectively).	sero	140-144	capsid protein;pre-capsid protein	Hepatitis B virus	134-139
17196133-7	2006	When the duration of treatment reached 1 year and 1.5 years, HBV DNA rebound rate in the patients (40.0% and 40.0% respectively) with HBeAg sero-conversion was obviously less (chi2 = 12.424, 10.237, P<0.01) than in those without sero-conversion (88.2% and 85.0% respectively).	sero	232-236	capsid protein;pre-capsid protein	Hepatitis B virus	134-139
15820118-10	2005	After fitting a frailty Cox model, results showed that sero-conversion in susceptible animals after infection using donors, in which presence of virus before the experiment started was confirmed, increased the hazard of sero-conversion two times in comparison with donors in which virus presence was not confirmed before start of the experiment.	sero	55-59	cytochrome c oxidase subunit 8A	Homo sapiens	24-27
15227880-11	2003	We have demonstrated that basing ANC sero-surveillance in urban areas of Afar Region over-samples urban residents of Amhara ethnicity and yields a major over-estimation of overall HIV-1 prevalence for the Region.	sero	37-41	aldo-keto reductase family 7 member A2	Homo sapiens	73-77
12584747-8	2003	Using a secondary SEREX approach we could detect sero-reactivity in sera of CTCL patients against recombinant cTAGE-1 (10/29), GAGE (3/19), MAGE-A1 (1/18), -A3 (1/18), -A6 (2/18) and -A9 (4/18) protein, but not against LAGE-1a, MAGE-A4b or MAGE-A12 protein (n = 19).	sero	49-53	MAGE family member A1	Homo sapiens	140-147
12584747-8	2003	Using a secondary SEREX approach we could detect sero-reactivity in sera of CTCL patients against recombinant cTAGE-1 (10/29), GAGE (3/19), MAGE-A1 (1/18), -A3 (1/18), -A6 (2/18) and -A9 (4/18) protein, but not against LAGE-1a, MAGE-A4b or MAGE-A12 protein (n = 19).	sero	49-53	MAGE family member A12	Homo sapiens	240-248
11843933-11	2001	The number of macrophages staining for iNOS, per field, under a magnification of x40, was increased in sero-positive patients (13.3 +/- 1.3 versus 9.9 +/- 0.7; P = 0.01).	sero	103-107	nitric oxide synthase 2	Homo sapiens	39-43
11494027-6	2001	Twenty-two of 24 (92%) sero-positive patients had mutations in their p53 gene while only 22 of 64 (34%) sero-negative patients had p53 mutations (p<0.01).	sero	23-27	tumor protein p53	Homo sapiens	69-72
11494027-10	2001	Most of the p53 deletions in sero-negative patients were however located outside conserved regions (seven of eight deletions).	sero	29-33	tumor protein p53	Homo sapiens	12-15
11494027-13	2001	Cellular protein binding to p53 or individual differences of major histocompatibility complex based presentation of p53 protein sequences by immune cells is therefore the most likely explanation between sero-negative and sero-positive patients.	sero	203-207	tumor protein p53	Homo sapiens	28-31
11494027-13	2001	Cellular protein binding to p53 or individual differences of major histocompatibility complex based presentation of p53 protein sequences by immune cells is therefore the most likely explanation between sero-negative and sero-positive patients.	sero	203-207	tumor protein p53	Homo sapiens	116-119
11494027-13	2001	Cellular protein binding to p53 or individual differences of major histocompatibility complex based presentation of p53 protein sequences by immune cells is therefore the most likely explanation between sero-negative and sero-positive patients.	sero	221-225	tumor protein p53	Homo sapiens	28-31
11494027-13	2001	Cellular protein binding to p53 or individual differences of major histocompatibility complex based presentation of p53 protein sequences by immune cells is therefore the most likely explanation between sero-negative and sero-positive patients.	sero	221-225	tumor protein p53	Homo sapiens	116-119
2968871-7	1988	When compared to the seronegative control and sero + NML groups, the sero + LOW group exhibited significant reductions in the percentage of MC expressing IL2R, the proportion of CD4 cells expressing IL2R, and the proportion of CD8 cells expressing IL2R.	sero	46-50	CD4 molecule	Homo sapiens	178-181
11725909-15	2001	This study indicates that GM-CSF is a potent HB vaccine adjuvant for sero-conversion in primary non-responders.	sero	69-73	colony stimulating factor 2	Homo sapiens	26-32
10762455-4	2000	Autoantibodies binding to modified LDL, cardiolipin and prothrombin have been associated with atherosclerosis and its thrombotic complications in sero-epidemiological studies.	sero	146-150	coagulation factor II, thrombin	Homo sapiens	56-67
10627886-8	1999	Fasting gastrin concentrations were significantly higher in patients who were H. pylori-seropositive (59 ng/l, 54-64 vs. sero-negative 41 ng/l, 37-46) (p = 0.002), and there was no increase in circulating gastrin concentrations with increasing age in either the H. pylori-positive or the H. pylori-negative group.	sero	88-92	gastrin	Homo sapiens	8-15
10204128-6	1999	Over the ten year period two of the 160 retested workers (1.25%) had sero-converted to anti HBc positive, yielding an incidence density of 0.27 cases per 100 person-years exposed in unvaccinated workers.	sero	69-73	keratin 88, pseudogene	Homo sapiens	92-95
8194900-0	1994	Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9.	sero	14-18	mucin 1, cell surface associated	Homo sapiens	43-47
8877212-4	1993	CSF was examined in 13 of the sero-positive patients.	sero	30-34	colony stimulating factor 2	Homo sapiens	0-3
2458872-3	1988	Low, but significant, levels of tumour necrosis factor alpha (TNF-alpha) were present in the majority of synovial fluids obtained from rheumatoid arthritis patients with a sero-positive history.	sero	172-176	tumor necrosis factor	Homo sapiens	62-71
2458872-4	1988	Low levels of interferon (IFN)-alpha and IFN-gamma were also detected, but only IFN-alpha was significantly increased in the sero-positive group.	sero	125-129	interferon alpha 1	Homo sapiens	80-89
2844457-2	1988	A significantly impaired uptake of 3H-thymidine by CD4 cells was found in BD, as compared with healthy HSV1 sero-positive subjects.	sero	108-112	CD4 molecule	Homo sapiens	51-54
2844457-7	1988	CD8 cells showed generally rather a low uptake of 3H-thymidine, nevertheless, the values in BD and recurrent herpetic infection were again lower than those in sero-positive controls or rheumatoid arthritis.	sero	159-163	CD8a molecule	Homo sapiens	0-3
9683831-1	1998	We measured the sero-positivity rate of serum alpha-fetoprotein (alphaFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis.	sero	16-20	alpha fetoprotein	Homo sapiens	46-63
9683831-1	1998	We measured the sero-positivity rate of serum alpha-fetoprotein (alphaFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis.	sero	16-20	alpha fetoprotein	Homo sapiens	65-72
23899395-5	1998	Stratifying the exposed workers by degree of VC exposure in estimated ppm-years by quartiles yielded a statistically significant trend for increasing odds ratio for sero-positivity of the p21ras biomarker with increasing exposure.	sero	165-169	HRas proto-oncogene, GTPase	Homo sapiens	188-194
9093834-2	1997	The predicted loops 1 and 4 are surface exposed and carry in their apices the sero-subtype epitopes P1.7 (loop 1) or P1.16 (loop 4), respectively.	sero	78-82	family with sequence similarity 72, member A	Mus musculus	100-104
8558745-7	1996	Progression to CTD occurred in 2.0% of patients in the spast,sero-group and 8.5% of patients in the obst,sero- group.	sero	61-65	CTD	Homo sapiens	15-18
8558745-7	1996	Progression to CTD occurred in 2.0% of patients in the spast,sero-group and 8.5% of patients in the obst,sero- group.	sero	105-109	CTD	Homo sapiens	15-18
7750732-1	1995	The meningococcal porA gene encodes the class 1 outer membrane protein which contains the VR1 and VR2 regions responsible for sero-subtype specificity.	sero	126-130	vault RNA 1-1	Homo sapiens	90-93
7750732-1	1995	The meningococcal porA gene encodes the class 1 outer membrane protein which contains the VR1 and VR2 regions responsible for sero-subtype specificity.	sero	126-130	vault RNA 1-2	Homo sapiens	98-101
2968871-7	1988	When compared to the seronegative control and sero + NML groups, the sero + LOW group exhibited significant reductions in the percentage of MC expressing IL2R, the proportion of CD4 cells expressing IL2R, and the proportion of CD8 cells expressing IL2R.	sero	46-50	CD8a molecule	Homo sapiens	227-230
3023483-4	1986	Those sero-positive patients consisted of four cases with IgG antibodies reactive mainly to the gag p24 and/or p15, four with IgM antibodies mainly to the gag p24 and/or p19, and three with both IgG and IgM antibodies.	sero	6-10	transmembrane p24 trafficking protein 2	Homo sapiens	100-103
3023483-4	1986	Those sero-positive patients consisted of four cases with IgG antibodies reactive mainly to the gag p24 and/or p15, four with IgM antibodies mainly to the gag p24 and/or p19, and three with both IgG and IgM antibodies.	sero	6-10	cyclin dependent kinase inhibitor 2B	Homo sapiens	111-114
3023483-4	1986	Those sero-positive patients consisted of four cases with IgG antibodies reactive mainly to the gag p24 and/or p15, four with IgM antibodies mainly to the gag p24 and/or p19, and three with both IgG and IgM antibodies.	sero	6-10	interleukin 23 subunit alpha	Homo sapiens	170-173
30787260-10	2019	These data indicate that UGDH expression and localization are an early sero-diagnostic marker in addition to a poor prognostic indicator in lung AC patients.	sero	71-75	UDP-glucose 6-dehydrogenase	Homo sapiens	25-29
6428222-1	1984	We studied the distribution of HLA-A, B, C, and -DR antigens in 77 Caucasian patients with sero-positive rheumatoid arthritis.	sero	91-95	major histocompatibility complex, class I, A	Homo sapiens	31-51
32555598-6	2020	RESULTS: 120 asymptomatic individuals of 308 rK39 sero-positives were DAT positive comprising of 56 with previous history and 64 with no history of VL.	sero	50-54	keratin 39	Rattus norvegicus	45-49
6313292-6	1983	The use of IN modified live and the aerosolized vaccine resulted in a greater immune response to the PI3 virus (60-80% sero-conversion) than did the temperature sensitive vaccine (20% sero-conversion).	sero	119-123	elafin	Bos taurus	101-104
317533-3	1979	We found mainly an increase of serum IgA, a decrease of IgM, a low level of circulating immune complexes, sometimes IgG type antiglobulin factor (very seldom IgM type, which explains the sero-negativity) seldom antinuclear antibodies; we found also a diminution of T lymphocytes detected by a decrease of E rosette - forming cells and an increase of the lymphocyte subpopulation forming high avidity EA rosettes, whereas the mitogenic response is normal or slightly decreased in the presence of Con A (not significant).	sero	187-191	immunoglobulin heavy variable 4-38-2-like	Homo sapiens	37-40
29933374-2	2018	METHODS: CD4 cell count at HIV sero-conversion and square root of CD4 cell decline were obtained using the CD4 decline in a cohort of HIV-infected persons in the UK, fitting random effect (slope and intercept) multilevel linear regression models.	sero	31-35	CD4 molecule	Homo sapiens	9-12
28744024-8	2017	Larger transmission clusters of URFs (BF1 and 01B) were observed among MSM who mostly were sero-diagnosed in recent time.	sero	91-95	forkhead box G1	Homo sapiens	38-49
29192630-17	2017	CONCLUSION: HCC patients who are sero-positive for DCP and sero-negative for AFP have significantly higher levels of serum ALT; serum ALT levels may be of diagnostic importance in AFP-negative, HBV-related HCC patients.	sero	33-37	alpha fetoprotein	Homo sapiens	180-183
30009061-0	2018	A Case of Euthyroid Graves" Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody.	sero	56-60	thyroid stimulating hormone receptor	Homo sapiens	74-86
29034470-7	2018	The data obtained from the in silico study demonstrate that a significant number of genes modulated in the liver of ConA-challenged mice belong to the Nrf2 pathway; on the other hand, the administration of CORM-A1 determines an improvement in several sero-immunological and histological parameters, and it is able to modulate genes identified by the in silico analysis.	sero	251-255	nuclear factor, erythroid derived 2, like 2	Mus musculus	151-155
27838939-1	2017	BACKGROUND: Aquaporin-4 (AQP4) antibody sero-positivity is critically important in neuromyelitis optica (NMO).	sero	40-44	aquaporin 4	Homo sapiens	12-23
27838939-1	2017	BACKGROUND: Aquaporin-4 (AQP4) antibody sero-positivity is critically important in neuromyelitis optica (NMO).	sero	40-44	aquaporin 4	Homo sapiens	25-29
27433127-4	2016	RESULTS: The serological survey of pigs showed the increase of IgM sero-positivity against JEV in July or August, and it was maintained until October or November in both Isahaya and Goto every year.	sero	13-17	Ig kappa chain	Sus scrofa	63-66
29560661-6	2017	RESULTS: Among the 19 DPB1 alleles analyzed in this study, DPB1*15:01 allele was more frequent in the spontaneous sero-converted control group compared to CHB patients (15.3% vs. 1.1%, chi2 = 12.5, OR = 0.06, 95% CI = 0.08-0.046 P < 0.001, Pcorrected < 0.001).	sero	114-118	major histocompatibility complex, class II, DP beta 1	Homo sapiens	59-63
28338507-7	2017	NY-ESO-1 antibodies were observed in 4 patients at the baseline (sero-positive) and augmented in all patients after vaccination.	sero	65-69	cancer/testis antigen 1A	Homo sapiens	0-8
28190118-7	2017	The concentration of RANKL was significantly higher in patients compared with controls, median (IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001), and in anti-CCP2-positive patients compared with sero-negative individuals.	sero	207-211	TNF superfamily member 11	Homo sapiens	21-26
27448505-6	2016	The study indicated the potential utility of rNS3DeltaHD fusion protein as candidate diagnostic reagent in developing an indirect-ELISA for sero-surveillance of animals for BTV antibodies under DIVA strategy, wherever monovalent/polyvalent killed BT vaccine formulations devoid of NS proteins are being practiced for immunization.	sero	140-144	mal, T-cell differentiation protein	Rattus norvegicus	45-49